NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

SBI Life Insurance Reports 6% YoY Growth in New Business APE

SBI Life Insurance (SBILIFE) has released its recent performance metrics, revealing a 6% year-over-year (YoY) growth in new business Annual Premium Equivalent (APE) to INR57.5 billion, which aligns with market expectations. This growth trend continued throughout the fiscal year, with APE increasing by 13% YoY to INR242.7 billion for FY26.

The company's Value of New Business (VNB) also showed a decline of 2% YoY to INR16.3 billion, resulting in a VNB margin of 28.3% for the quarter, compared to 30.5% in 4QFY25. However, this decline is in line with market expectations. For the fiscal year FY26, VNB grew by 12% YoY to INR66.7 billion, with a VNB margin of 27.5%, which is at the upper end of the company's guidance of 26-28%.

Outlook and Revised Estimates

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Motilal Oswal's research team has revised its estimates for SBI Life Insurance, expecting a 2% decline in Value of New Business to Enterprise Value (VNB/EV) estimates for both FY27 and FY28, while maintaining an expected Compound Annual Growth Rate (CAGR) of 14% over FY26-28E. The operating Return on Embedded Value (RoEV) is expected to remain stable at 18%.

Revised Recommendation

Based on these revised estimates, Motilal Oswal has reiterating its BUY rating for SBI Life Insurance with a revised Target Price (TP) of INR2,350, calculated based on a Price-to-Embedded Value (P/EV) ratio of 2.1x for FY28E.

Investor Takeaway

Motilal Oswal maintains a buy recommendation for SBI Life Insurance with a target price of Rs 2350.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.